| 8.5 0.02 (0.24%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.19 | 1-year : | 10.86 |
| Resists | First : | 8.73 | Second : | 9.3 |
| Pivot price | 8.43  |
|||
| Supports | First : | 7.8 | Second : | 6.48 |
| MAs | MA(5) : | 8.43 |
MA(20) : | 8.46 |
| MA(100) : | 8.88 |
MA(250) : | 9.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.7 | D(3) : | 41.9 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 11.8 | Low : | 7.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRTA ] has closed below upper band by 40.2%. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.66 - 8.69 | 8.69 - 8.71 |
| Low: | 8.36 - 8.4 | 8.4 - 8.44 |
| Close: | 8.44 - 8.5 | 8.5 - 8.55 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Tue, 20 Oct 2026
Prothena's Partnership Strategy: Growth Driver or Limitation? - Yahoo Finance
Tue, 20 Oct 2026
Prothena stock trades at EUR 7.54 with USD 445 million market value - ad-hoc-news.de
Thu, 15 Oct 2026
Prothena Corp Public Ltd Insider Bought Shares Worth $920,049, According to a Recent SEC Filing - Moomoo
Tue, 13 Oct 2026
(PRTA) Risk Channels and Responsive Allocation - Stock Traders Daily
Fri, 02 Oct 2026
A development chief is leaving Prothena (PRTA) to join one of its strategic partners. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.444e+007 (%) |
| Held by Institutions | 22.3 (%) |
| Shares Short | 8,500 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.904e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -80.7 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 850.2 % |
| Return on Equity (ttm) | -10.7 % |
| Qtrly Rev. Growth | 5.453e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.45 |
| Dividend | 0 |
| Forward Dividend | 8.01e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|